Navigation Links
Biopharmaceutical infrastructure key to lower drug development costs
Date:10/11/2007

lion or 23 percent.

Data for the study were gathered from individual researchers and organizations including a survey of 44 technical experts whose companies represent 42 percent of the combined annual R&D spending and 49 percent of the combined annual R&D sales in biopharmaceuticals.

The ultimate beneficiaries of an improved biopharmaceutical infrastructure, wrote the studys authors, "are patients who gain access to a broader array of novel therapies where development is supported by an effective technology infrastructure."

The full report, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry, is available at: www.nist.gov/director/prog-ofc/report07-1.pdf.

* RTI International, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry: Planning Report 07-01, August 2007, 201 pp.


'/>"/>
Contact: Gail Porter
gail.porter@nist.gov
301-975-3392
National Institute of Standards and Technology (NIST)
Source:Eurekalert

Page: 1 2

Related biology news :

1. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
2. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
3. Medical whistleblowers speak out
4. The evolutionary triumph of flower power
5. Bumblebees copy one another when contending with unfamiliar flowers
6. Analysis of flower genes reveals the fate of an ancient gene duplication
7. Gene therapy to lower blood pressure just enough
8. Long-sought flower-inducing molecule found
9. FDA: Highly Unlikely Green Tea Lowers Cancer Risk
10. Divergent mating systems and parental conflict as a barrier to hybridization in flowering plants
11. Reducing antibiotic use lowers rates of drug-resistant bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... studies reveal that voting decisions are more associated ... a politician,s appearance than to positive ones, says ... of Technology (Caltech), Scripps College, Princeton University, and ... particularly true when voters have little or no ...
... beware. Chances are your male partner is on your ... even when you have kept to the straight and ... constant vigilance, women may be better than men at ... in Richmond and colleagues gave 203 young heterosexual couples ...
... sustainability expert Deane Evans will provide an introduction to the basics of ... seminar, open to the public, at NJIT. The talk, set ... a review of the status of the NJ schools, construction program. ... Evans, a registered architect, is executive director ...
Cached Biology News:Caltech-led researchers find negative cues from appearance alone matter for real elections 2Caltech-led researchers find negative cues from appearance alone matter for real elections 3Caltech-led researchers find negative cues from appearance alone matter for real elections 4Men are better at detecting infidelities 2
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... May 17 ViroPharma Incorporated (Nasdaq: VPHM ) ... [Human]), its product proven to prevent attacks of hereditary angioedema (HAE), ... needle-less reconstitution system. This simple-to-use reconstitution device and accompanying training materials ... , , ...
... to Highlight Latest Biomedical Licensing Opportunities , ... KANSAS CITY, Mo. , ... not-for-profit Kauffman Innovation Network, Inc., today announced that it is continuing ... Health Network (UHN), a group of leading research hospitals and institutes ...
... 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, ... specialized in oncology and endocrinology, today announced that it ... designation from the Committee for Orphan Medicinal Products (COMP) ... for the treatment of ovarian cancer. AEZS-108, the Company,s ...
Cached Biology Technology:ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 2ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 3ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 4ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 5The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
... surface is produced by a patented microwave ... giving more consistent, even cell attachment, increased ... attachment and growth uunder difficult conditions, including ... may provide a more ecominic alternative to ...
... array system, 100-240 V, uses multiplex suspension ... analysis of up to 100 proteins and ... suspension array is composed of up to ... may be conjugated with a unique reactant ...
... PYREX Delong style shaker flasks have three ... agitation of solutions to improve oxygen or ... reciprocating shakers. The long neck reduces splashing ... Their uniform wall thickness provides the proper ...
Biology Products: